What's Next in Immunotherapy?

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

During the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs, Capitini emphasized that all cancers should eventually find benefit in immunotherapy. With expansion in renal cell carcinoma (RCC), lung cancer and head and neck cancer, that change may be underway.